Overview

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases

Status:
Not yet recruiting

Trial end date:
2028-03-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases (including but not restricted to) of malignant melanoma.

Phase:

Phase 1

Details

Lead Sponsor:

Vastra Gotaland Region

Collaborator:

Miltenyi Biomedicine GmbH

Treatments:

Interleukin-2
Melphalan